无法在这个位置找到： ”baidu_js_push.htm”
今日热点推荐：
爱地那非是什么？悦康“爱力士”
加入收藏 | 设为首页 | 热门搜索 |
网站地图
CD47靶向疗法初步临床结果积极 总缓解率高达92%(2)
2020-06-03 未知 admin
[1] Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia，Retrieved December 10, 2019, from https://ir.fortyseveninc.com/news-releases/news-release-details/forty-seven-inc-announces-updated-data-ongoing-clinical-trial
[2] Forty Seven Presentation，Retrieved December 10, 2019, from https://ir.fortyseveninc.com/static-files/2e1f44ac-9537-4f6e-94a3-6ed148b781a3
原标题：ASH | 92%总缓解率！CD47靶向疗法初步临床结果积极
*声明：本文由入驻新浪医药新闻作者撰写，观点仅代表作者本人，不代表新浪医药新闻立场。▽关注【药明康德】微信公众号
鐑瘝锛�
